The S100A13 antibody is a crucial tool in studying the S100A13 protein, a member of the calcium-binding S100 protein family. S100A13 is involved in diverse cellular processes, including cell proliferation, differentiation, and inflammatory responses. It plays a notable role in the non-classical secretion pathway of fibroblast growth factor 1 (FGF1) and interacts with other proteins, such as the copper chaperone CCS, influencing oxidative stress responses. Dysregulation of S100A13 has been linked to pathologies like cancer, cardiovascular diseases, and neurological disorders, making it a potential biomarker or therapeutic target.
The S100A13 antibody, typically developed in hosts like rabbits or mice, enables detection and quantification of the protein in various experimental settings. It is widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to analyze S100A13 expression levels, subcellular localization, and interactions in tissues or cell lines. Researchers rely on its specificity to explore S100A13's role in disease mechanisms, such as tumor angiogenesis, neuronal damage after stroke, or cardiomyocyte apoptosis. Validation via knockout controls or peptide blocking ensures antibody reliability. Commercial availability from multiple suppliers has facilitated its application in cancer research, neurobiology, and cardiovascular studies, underscoring its importance in both basic and translational research.